Captrust Financial Advisors An2 Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 28,667 shares of ANTX stock, worth $31,533. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,667
Previous 28,667
-0.0%
Holding current value
$31,533
Previous $93,000
34.41%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
49Shares Held
25.6MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.32 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.55MShares$6.11 Million0.18% of portfolio
-
Octagon Capital Advisors LP New York, NY3.22MShares$3.54 Million1.6% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.09MShares$2.3 Million0.26% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.71 Million0.5% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $21.3M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...